((自动化翻译由路透提供，请见免责声明 ))
12月12日 -
** Candel Therapeutics 在本周股价大涨后寻求融资，盘后股价下跌17%至8.13美元
* () * 总部位于马萨诸塞州尼德姆的公司启动了8000万美元的发行计划，包括股票和预先筹资的认股权证
** 周三，CADL公司称其前列腺癌疗法CAN-2409在后期研究中达到了主要目标 ()，公司股价大涨68%，收于7.75美元。
** 周四股价上涨 26.5%，收于 9.80 美元
** 公司计划将募集资金净额用于准备提交 CAN-2409 的生物制品许可申请和一般用途
** 花旗集团、美国银行和 Canaccord Genuity 担任此次发行的簿记管理人
** 已发行股票约 3 250 万股，公司市值约 3.2 亿美元
** 2023 年底股价为 1.47 美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.